Login to Your Account



NewCo News: Mimetogen Launches Phase II Trial of Topical NGF in Dry Eye

By Vicki Brower


Wednesday, January 19, 2011
Focusing on ophthalmic diseases with its portfolio of small-molecule nerve growth factor (NGF) mimetic compounds, Mimetogen Pharmaceuticals Inc. is capitalizing on a large, relatively underserved medical market that is growing at about twice the rate of the general pharmaceutical sector: ophthalmology.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription